5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-1H-pyrazole-3-acetamide
| Title | Journal |
|---|---|
| Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles. | Molecular cancer therapeutics 20170601 |
| Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. | Investigational new drugs 20130401 |
| Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. | Cancer chemotherapy and pharmacology 20120901 |
| Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). | Investigational new drugs 20120801 |
| The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. | British journal of cancer 20120227 |
| Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen. | ACS chemical biology 20120120 |
| Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. | Blood 20111201 |
| A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. | Leukemia research 20111001 |
| A novel cell-based, high-content assay for phosphorylation of Lats2 by Aurora A. | Journal of biomolecular screening 20110901 |
| Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas. | Biochemical pharmacology 20110501 |
| Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition. | Radiation research 20110401 |
| Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110301 |
| Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. | British journal of cancer 20110301 |
| Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20110201 |
| AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. | Endocrine-related cancer 20110201 |
| Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase. | Journal of medicinal chemistry 20110113 |
| P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. | BMC cancer 20110101 |
| Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. | Cancer research 20101201 |
| Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro. | International journal of cancer 20101001 |
| Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor. | Journal of medicinal chemistry 20100909 |
| Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. | Journal of medicinal chemistry 20100527 |
| Aurora kinase inhibitors as anti-cancer therapy. | Anti-cancer drugs 20100401 |
| The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. | Journal of hepatology 20100101 |
| Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. | Molecular cancer 20100101 |
| Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091101 |
| The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. | Cell cycle (Georgetown, Tex.) 20091001 |
| Mitotic drivers--inhibitors of the Aurora B Kinase. | Cancer metastasis reviews 20090601 |
| Pharmacological inhibition of aurora-A but not aurora-B impairs interphase microtubule dynamics. | Cell cycle (Georgetown, Tex.) 20090601 |
| AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. | Cancer research 20090515 |
| Discovery and development of aurora kinase inhibitors as anticancer agents. | Journal of medicinal chemistry 20090514 |
| Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. | The Biochemical journal 20090513 |
| Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152. | The pharmacogenomics journal 20090401 |
| The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090315 |
| Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. | Oncogene 20080522 |
| Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. | Haematologica 20080501 |
| Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. | Molecular cancer therapeutics 20080301 |
| The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. | British journal of haematology 20080201 |
| AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. | Blood 20070915 |
| AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070615 |
| Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. | Journal of medicinal chemistry 20070503 |
| Aurora kinases: new targets for cancer therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061201 |
| Aurora kinases: shining lights on the therapeutic horizon? | Oncogene 20050728 |
| Aurora-kinase inhibitors as anticancer agents. | Nature reviews. Cancer 20041201 |